Divi's Labs signs agreement with global pharmaceutical company
Telangana: Divi's Laboratories has signed a long-term manufacturing and supply agreement with a global pharmaceutical company.
As part of the agreement, Divi’s will manufacture and supply advanced intermediates under commercially agreed terms. While the name of the partner and specific quantitative details remain undisclosed due to a confidentiality agreement, the company stated that it anticipates a meaningful contribution to revenue from this deal.
In a filing with the BSE, Divi’s noted, “The Agreement will benefit the customer with assured supply and the Company to expand its presence in custom synthesis.”
In addition, Divi’s announced plans for capacity addition at its manufacturing facilities with an estimated investment ranging between Rs 650 crore and Rs 700 crore, to be funded from internal accruals.
Read also: High level delegation from USFDA visits Divi's Labs Choutuppal facility
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.